Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

University of Alabama at Birmingham, Birmingham, Alabama, United States

Mayo Clinic-AZ, Phoenix, Arizona, United States

City of Hope, Duarte, California, United States

University of California-Los Angeles, Los Angeles, California, United States

University of California-San Francisco, San Francisco, California, United States

University of Colorado Denver, Aurora, Colorado, United States

Mayo Clinic-Jacksonville, Jacksonville, Florida, United States

University of Miami, Miami, Florida, United States

Moffit Cancer Center, Tampa, Florida, United States

Emory University, Atlanta, Georgia, United States

Northwestern University Medical Hospital, Chicago, Illinois, United States

John Hopkins Cancer Center, Baltimore, Maryland, United States

Massachusetts General Hospital, Boston, Massachusetts, United States

Dana Farber Cancer Institute, Boston, Massachusetts, United States

Karmanos Cancer Center, Detroit, Michigan, United States

Washington University, St Louis, Missouri, United States

Memorial Sloan Kettering Cancer Center, New York, New York, United States

Cornell Cancer Center, New York, New York, United States

Duke Cancer Center, Durham, North Carolina, United States

Cleveland Clinic, Cleveland, Ohio, United States

Ohio State University, Columbus, Ohio, United States

Oregon Health and Science University, Portland, Oregon, United States

Medical University of South Carolina, Charleston, South Carolina, United States

Sarah Cannon Research Institute, Nashville, Tennessee, United States

UT Southwestern Medical Center, Dallas, Texas, United States

MD Anderson Cancer Center, Houston, Texas, United States

Hopital La Timone, Marseille, France

Hopital Haut-Leveque, Pessac, France

Central Lyon Sud, Pierre-Bénite, France

Institute Gustave Roussly (IGR), Villejuif, France